More on CAPR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.82 |
|
|||
| Open | $25.41 | ||||
| 52 Wk High | $5.40 | ||||
| 52 Wk Low | $1.88 | ||||
| Day High | $28.89 | ||||
| Day Low | $25.08 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,340,316 | ||||
- Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
- Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
- Form SCHEDULE 13G/A CAPRICOR THERAPEUTICS, Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
- Form S-8 CAPRICOR THERAPEUTICS,
- Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
- Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: TANG CAPITAL MANAGEMENT LLC
- CAPR receives FDA request for clinical study report on Deramiocel
- Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
- Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
- Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
Entities mentioned with CAPR
- FDA | View Related Stories »
- Twitter | View Related Stories »
- S3 | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
